These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30561237)

  • 1. The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis.
    Shima Y
    Mod Rheumatol; 2019 Mar; 29(2):294-301. PubMed ID: 30561237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis.
    Sakkas LI
    Drug Des Devel Ther; 2016; 10():2723-8. PubMed ID: 27621593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy.
    Shima Y
    Cells; 2021 May; 10(5):. PubMed ID: 34064515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical contribution of the interleukin-6/signal transducer and activator of transcription 3 axis to vasculopathy associated with systemic sclerosis.
    Taniguchi T; Asano Y; Fukasawa T; Yoshizaki A; Sato S
    J Dermatol; 2017 Aug; 44(8):967-971. PubMed ID: 28342234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis.
    Olewicz-Gawlik A; Danczak-Pazdrowska A; Kuznar-Kaminska B; Gornowicz-Porowska J; Katulska K; Trzybulska D; Batura-Gabryel H; Silny W; Poplawski D; Hrycaj P
    Int J Rheum Dis; 2014 Jul; 17(6):664-70. PubMed ID: 24467649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature.
    Zacay G; Levy Y
    Best Pract Res Clin Rheumatol; 2018 Aug; 32(4):563-571. PubMed ID: 31174825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.
    Shima Y; Kuwahara Y; Murota H; Kitaba S; Kawai M; Hirano T; Arimitsu J; Narazaki M; Hagihara K; Ogata A; Katayama I; Kawase I; Kishimoto T; Tanaka T
    Rheumatology (Oxford); 2010 Dec; 49(12):2408-12. PubMed ID: 20819796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The significance of interleukin-6 and C-reactive protein in systemic sclerosis: a systematic literature review.
    Muangchant C; Pope JE
    Clin Exp Rheumatol; 2013; 31(2 Suppl 76):122-34. PubMed ID: 23910616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the effect of Bosentan treatment on proinflammatory cytokine serum levels in patients affected by Systemic Sclerosis.
    Bellisai F; Morozzi G; Scaccia F; Chellini F; Simpatico A; Pecetti G; Galeazzi M
    Int J Immunopathol Pharmacol; 2011; 24(1):261-4. PubMed ID: 21496413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis.
    Hasegawa M; Sato S; Fujimoto M; Ihn H; Kikuchi K; Takehara K
    J Rheumatol; 1998 Feb; 25(2):308-13. PubMed ID: 9489824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 6 in systemic sclerosis and potential implications for targeted therapy.
    Muangchan C; Pope JE
    J Rheumatol; 2012 Jun; 39(6):1120-4. PubMed ID: 22505699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung disease.
    Numajiri H; Yoshizaki A; Fukasawa T; Ebata S; Nakamura K; Yamashita T; Saigusa R; Miura S; Hirabayashi M; Yoshizaki A; Sumida H; Asano Y; Kazoe Y; Mawatari K; Kitamori T; Sato S
    J Dermatol; 2018 Oct; 45(10):1221-1224. PubMed ID: 30051925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interleukin-2 and interleukin-6 in serum as markers of disease progression in systemic sclerosis].
    Lis A; Brzezińska-Wcisło L
    Pol Merkur Lekarski; 2001 Sep; 11(63):206-9. PubMed ID: 11761811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of blocking IL-6 outside of rheumatoid arthritis: current perspective.
    Murakami M; Nishimoto N
    Curr Opin Rheumatol; 2011 May; 23(3):273-7. PubMed ID: 21427577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions.
    Mathian A; Parizot C; Dorgham K; Trad S; Arnaud L; Larsen M; Miyara M; Hié M; Piette JC; Frances C; Yssel H; Amoura Z; Gorochov G
    Ann Rheum Dis; 2012 Jul; 71(7):1227-34. PubMed ID: 22696687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum IL-15 in patients with early systemic sclerosis: a potential novel marker of lung disease.
    Wuttge DM; Wildt M; Geborek P; Wollheim FA; Scheja A; Akesson A
    Arthritis Res Ther; 2007; 9(5):R85. PubMed ID: 17784951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum levels of interleukin-18-binding protein isoform a: Clinical association with inflammation and pulmonary hypertension in systemic sclerosis.
    Nakamura K; Asano Y; Taniguchi T; Minatsuki S; Inaba T; Maki H; Hatano M; Yamashita T; Saigusa R; Ichimura Y; Takahashi T; Toyama T; Yoshizaki A; Miyagaki T; Sugaya M; Sato S
    J Dermatol; 2016 Aug; 43(8):912-8. PubMed ID: 26777734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective role of interleukin-6 in systemic sclerosis gastrointestinal tract involvement: case report and review of the literature.
    Frech TM; Hudson M
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S179-81. PubMed ID: 26339896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders.
    Stuart RA; Littlewood AJ; Maddison PJ; Hall ND
    Clin Exp Rheumatol; 1995; 13(1):17-22. PubMed ID: 7774098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Demonstration of interleukin 8 and autoantibodies to interleukin 8 in the serum of patients with systemic sclerosis and related disorders.
    Reitamo S; Remitz A; Varga J; Ceska M; Effenberger F; Jimenez S; Uitto J
    Arch Dermatol; 1993 Feb; 129(2):189-93. PubMed ID: 8434976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.